Loading
A phase 1/2 trial of Vepdegestrant and Ribociclib in advanced solid tumours, run by Pfizer, active and no longer recruiting.
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) is a phase 1/2 interventional study registered as NCT05573555 by Pfizer, with 20 participants enrolled, started 2023-03-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: ARV-471 and Ribociclib.
Shares Vepdegestrant, CDK4/6 inhibitors, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Vepdegestrant, CDK4/6 inhibitors, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Vepdegestrant, CDK4/6 inhibitors, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Vepdegestrant, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs), Pfizer (incl. Seagen) and the tag pipeline.
Shares Ribociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ribociclib, CDK4/6 inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CDK4/6 inhibitors, Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.